Evidence map›Paper›PMID 29059561›Full record

ArticleChemosphere2018

Effects of chlorpyrifos and trichloropyridinol on HEK 293 human embryonic kidney cells.

Jeanette M Van Emon, Peipei Pan, Frank van Breukelen

Open access · greenAbstract read
In one paragraph

Article in Chemosphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Histopathological features of low-dose organophosphate exposure.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jeanette M Van EmonU. S. Environmental Protection Agency, National Exposure Research Laboratory, 944 E. Harmon Ave, Las Vegas, NV 89119, USA. Electronic address: vanemon.jeanette@epa.gov.
Peipei PanSchool of Life Sciences, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA.
Frank van BreukelenSchool of Life Sciences, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, NV 89154, USA.
University of Nevada, Las Vegas · USEnvironmental Protection Agency · US

Funding

Outreach/Diversity/Pipeline ProjectP20GM103440 · NIGMS · UNIVERSITY OF NEVADA RENO · PI Eduardo A Robleto · 2012 to 2026
$58.0M
Intramural EPA EPA999999NIGMS NIH HHS P20 GM103440
6 · The paper itself

Abstract

Chlorpyrifos (CPF) [O, O-diethyl -O-3, 5, 6-trichloro-2-pyridyl phosphorothioate] is an organophosphate insecticide widely used for agricultural and urban pest control. Trichloropyridinol (TCP; 3,5,6-trichloro-2-pyridinol), the primary metabolite of CPF, is often used as a generic biomarker of exposure for CPF and related compounds. Human embryonic kidney 293 (HEK 293) cells were exposed to CPF and TCP with varying concentrations and exposure periods. Cell cultures enable the cost-effective study of specific biomarkers to help determine toxicity pathways to predict the effects of chemical exposures without relying on whole animals. Both CPF and TCP were found to induce cytotoxic effects with CPF being more toxic than TCP with EC

Indexed as

AnimalsApoptosisChlorpyrifosEpithelial CellsHEK293 CellsHumansInsecticidesInterleukin-1alphaInterleukin-6ProteomePyridonesUp-Regulation3,5,6-trichloro-2-pyridinolChlorpyrifosIL6 protein, humanInsecticidesInterleukin-1alphaInterleukin-6ProteomePyridonesAdverse outcomeApoptosisBiomarkersChlorpyrifosCPFTCP

Identifiers

PMID29059561
PMCPMC7462251
OpenAlexW2763344536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.